Botox com­peti­tor Daxxi­fy hits $15.4M in Q1 earn­ings as mak­er faces trade se­crets law­suit

The sec­ond round of rev­enue num­bers is in for Daxxi­fy, Re­vance Ther­a­peu­tics’ longer-last­ing cos­met­ic in­jec­tion set to com­pete against Ab­b­Vie’s Botox.

Re­vance Ther­a­peu­tics on Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.